S2 Episode 6: Can Fluid Biomarkers Predict MS Progression?
Could NfL and GFAP redefine how clinicians track progression in MS? Dr Mark Freedman joins Dr Anne Cross to explain the evolving science behind these powerful biomarkers. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002608. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Fluid Biomarkers in Multiple Sclerosis: From Current to Future Applications https://pubmed.ncbi.nlm.nih.gov/39444698/ National Hospital for Neurology and Neurosurgery https://www.uclh.nhs.uk/our-services/our-hospitals/national-hospital-neurology-and-neurosurgery Neurofilament Biophysics: From Structure to Biomechanics https://pubmed.ncbi.nlm.nih.gov/38598299/ Glymphatic System: An Emerging Therapeutic Approach for Neurological Disorders https://pubmed.ncbi.nlm.nih.gov/37485040/ Axonal Transection in the Lesions of Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/9445407/ The Combination of CSF Neurofilament Light Chain and Glial Fibrillary Acidic Protein Improves the Prediction of Long-Term Confirmed Disability Worsening in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/39587121/ Amit Bar-Or, MD https://www.med.upenn.edu/apps/faculty/index.php/g324/p8937426 Anxiety, Depression, and Expanded Disability Status Scale Independently Predict the Perception of Disability in Persons With Multiple Sclerosis: A Cross-Sectional Study https://pubmed.ncbi.nlm.nih.gov/39839740/ Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria https://pubmed.ncbi.nlm.nih.gov/40975101/ Radiologically Isolated Syndrome: A 6-Year Follow-Up Study in Chile https://pubmed.ncbi.nlm.nih.gov/40120160/ Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights Into the Disease Pathophysiology, Diagnosis and Management https://pubmed.ncbi.nlm.nih.gov/33374173/
--------
27:42
--------
27:42
S2 Episode 5: Can Imaging Biomarker Breakthroughs Help Us See MS More Clearly?
How can imaging biomarkers enhance our understanding of MS? Dr Anne Cross and Dr Matthew Brier examine MRI advancements that provide new insights into diagnosis, progression, and treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002607. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Emerging MRI Biomarkers for the Diagnosis of Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/39511991/ Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/38079177/ Biomarkers for Diagnosis and Prognosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: Review Article https://pubmed.ncbi.nlm.nih.gov/40547008/ Update on Neuromyelitis Optica Spectrum Disorder https://pmc.ncbi.nlm.nih.gov/articles/PMC7771018/ Sjogren Syndrome https://emedicine.medscape.com/article/332125-overview Detection of Multiple Sclerosis Lesions by Susceptibility-Weighted Imaging: A Systematic Review and Meta-Analyses https://pubmed.ncbi.nlm.nih.gov/39406601/ The Central Vein Sign on T2*-Weighted Images as a Diagnostic Tool in Multiple Sclerosis: A Systematic Review and Meta-Analysis Using Individual Patient Data https://pubmed.ncbi.nlm.nih.gov/31796822/ Paramagnetic Rim Lesions Are Highly Specific for Multiple Sclerosis in Real-World Data https://pubmed.ncbi.nlm.nih.gov/39371137/ Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics https://pubmed.ncbi.nlm.nih.gov/30385472/ Slowly Expanding Lesions Are Associated With Disease Activity and Gray Matter Loss in Relapse-Onset Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/39390692/ TSPO PET in Multiple Sclerosis: Emerging Insights Into Pathophysiology, Prognosis, and Treatment Monitoring https://pubmed.ncbi.nlm.nih.gov/40450829/ An Update on the Use of Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Relapsing Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/36946625/
--------
27:26
--------
27:26
S2 Episode 4: Should Platform Therapies Remain First-Line in MS?
Drs Anne Cross and Scott Newsome discuss new horizons in MS treatment strategies, including the TREAT-MS trial and shared decision-making for optimal patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002606. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Sclerosis https://emedicine.medscape.com/article/1146199-overview Interferon Beta and Glatiramer Acetate Therapy https://pubmed.ncbi.nlm.nih.gov/23264098/ Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS) https://www.clinicaltrials.gov/study/NCT03500328 Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020 https://pubmed.ncbi.nlm.nih.gov/37428482/ What We Learned From the History of Multiple Sclerosis Measurement: Expanded Disability Status Scale https://pubmed.ncbi.nlm.nih.gov/30692861/ The Multiple Sclerosis Functional Composite Measure (MSFC): An Integrated Approach to MS Clinical Outcome Assessment. National MS Society Clinical Outcomes Assessment Task Force https://pubmed.ncbi.nlm.nih.gov/10467383/ Long-term Efficacy and Safety of Alemtuzumab in Participants With Highly Active MS: TOPAZ Clinical Trial and Interim Analysis of TREAT-MS Real-World Study https://pubmed.ncbi.nlm.nih.gov/39935588/ Imaging Outcome Measures for Progressive Multiple Sclerosis Trials https://pubmed.ncbi.nlm.nih.gov/29041865/ Current Use of Fluid Biomarkers as Outcome Measures in Multiple Sclerosis (MS): A Review of Ongoing Pharmacological Clinical Trials https://pubmed.ncbi.nlm.nih.gov/38117403/ Patient-reported Disability Progression Outcomes Among Patients With Multiple Sclerosis: Results of an Outcomes-Based Agreement https://pubmed.ncbi.nlm.nih.gov/39471272/ Insights for Healthcare Providers on Shared Decision-making in Multiple Sclerosis: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/38180727/ Practice Guideline Update Summary: Vaccine-Preventable Infections and Immunization in Multiple Sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology https://pubmed.ncbi.nlm.nih.gov/31462584/
--------
25:48
--------
25:48
S2 Episode 3: Progress in Progressive MS: BTK Inhibitors and the HERCULES Study
Can BTK inhibitors finally move the needle in progressive MS? Dr Robert Fox joins Dr Anne Cross to unpack the results of the HERCULES trial and explore what's next. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002605. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40202696/ Bruton Tyrosine Kinase Inhibitors in Multiple Sclerosis: Evidence and Expectations https://pubmed.ncbi.nlm.nih.gov/38533819/ Safety and Efficacy of Tolebrutinib, an Oral Brain-Penetrant BTK Inhibitor, in Relapsing Multiple Sclerosis: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/34418400/ Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis https://clinicaltrials.gov/study/NCT03996291 Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40202623/ Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS) https://clinicaltrials.gov/study/NCT04458051 Fenebrutinib, a Bruton's Tyrosine Kinase Inhibitor, Blocks Distinct Human Microglial Signaling Pathways https://pubmed.ncbi.nlm.nih.gov/39465429/ Rilzabrutinib, a Reversible Covalent Bruton's Tyrosine Kinase Inhibitor: Absorption, Metabolism, Excretion, and Absolute Bioavailability in Healthy Participants https://pubmed.ncbi.nlm.nih.gov/37060187/ Orelabrutinib: First Approval https://pubmed.ncbi.nlm.nih.gov/33704654/ Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/38648580/ Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/30157388/
--------
27:24
--------
27:24
S2 Episode 2: The Exercise Prescription for MS Just Got Stronger
Join Drs Anne Cross and Rob Motl as they discuss how new data and clinical insights are reshaping how exercise helps people with MS. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002604. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Intrathecal Baclofen for Multiple Sclerosis–Related Spasticity: A Twenty-Year Experience https://pubmed.ncbi.nlm.nih.gov/30366276/ Prevalence of Depression and Anxiety in Multiple Sclerosis: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/28017241/ Study Protocol: Exercise Training for Treating Major Depressive Disorder in Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/38632556/ CDMRP Multiple Sclerosis https://cdmrp.health.mil/msrp/default Effect of Exercise on Depressive Symptoms in Adults With Neurologic Disorders: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/25596001/ National MS Society Exercising With MS https://www.nationalmssociety.org/managing-ms/living-with-ms/diet-exercise-and-healthy-behaviors/exercise Moderators of Exercise Effects on Depressive Symptoms in Multiple Sclerosis: A Meta-regression https://pubmed.ncbi.nlm.nih.gov/28602542/ Physical Activity, Fitness, and Gray Matter Volume https://pubmed.ncbi.nlm.nih.gov/24952993/ Exercise-Mediated Neurogenesis in the Hippocampus via BDNF https://pubmed.ncbi.nlm.nih.gov/29467613/ Integrative CNS Plasticity With Exercise in MS: The PRIMERS (PRocessing, Integration of Multisensory Exercise-Related Stimuli) Conceptual Framework https://pubmed.ncbi.nlm.nih.gov/30205784/ Effects of Physical Exercise on Plasma Brain-Derived Neurotrophic Factor in Neurodegenerative Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials https://pubmed.ncbi.nlm.nih.gov/34087277/ Multimodal Enhancement of Remyelination by Exercise With a Pivotal Role for Oligodendroglial PGC1α https://pubmed.ncbi.nlm.nih.gov/30232000/ Cognitive Rehabilitation and Aerobic Exercise for Cognitive Impairment in People With Progressive Multiple Sclerosis (CogEx): A Randomised, Blinded, Sham-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/37739574/
Acerca de Medscape InDiscussion: Multiple Sclerosis
Listen to Medscape InDiscussion: Multiple Sclerosis, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/977030). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Escucha Medscape InDiscussion: Multiple Sclerosis, Psicologia Al Desnudo | @psi.mammoliti y muchos más podcasts de todo el mundo con la aplicación de radio.es
España